The Covid jabs nightmare looks as though it could get a whole lot worse. A Japanese study warns of risks in transfusing blood from COVID vaccine recipients to other patients, indicating it may cause significant health risks, including death. The researchers also call for safety measures to screen and secure the world’s blood supply.
Titled Transfusions of Blood Products Derived from Genetic Vaccine Recipients: Safety Concerns and Proposals for Specific Measures, the paper’s second version posted on Wednesday recalls the “global genetic vaccination program” that had been “rapidly implemented as a fundamental solution” to the coronavirus disease in 2020. The paper’s abstract continues:
However, it has been reported worldwide that the modified mRNAs encoding spike proteins and lipid nanoparticles, which are used as drug delivery systems, not only cause thrombosis and cardiovascular disorders post vaccination, but might also cause diverse diseases involving all organs and systems, including the nervous system.
Based on these reports and the abundant evidence that has come to light in the past few years, this paper aims to draw the attention of medical professionals to the various risks associated with transfusion using blood products derived from long COVID patients or from genetic vaccine recipients, and to make proposals regarding specific inspection items, testing methods, regulations, etc.
In his commentary on the relevance of the study, Dr. Joseph Mercola highlights the paper’s particular attention to the dangers such transfusions may have on neurological health. Blood infected with “prion-like structures” found within the spike protein, produced by these injections, may induce “the misfolding of normal proteins in the brain,” causing disorders.
“Prion diseases are characterized by a long incubation period, followed by rapid progression and high mortality,” he wrote. And the possibility that these spike proteins may include “prion-like domains” raises several concerns.
These include the risk of transmitting of such prion-like structures through blood transfusions with the risk of causing dangerous prion disease in recipients.
“Prion diseases are notoriously difficult to diagnose early, have no cure, and are fatal, making any potential transmission through blood products a significant safety concern,” Mercola wrote.
Furthermore, due to technical challenges and the historical rarity of prion disease, current screening processes do not test for these structures and may thus be inadequate in preventing such transmission.